A price for cost-effectiveness: Implications for recombinant human activated protein C (rhAPC)

被引：7
作者：
Chalfin, DB [1 ]
Teres, D
Rapoport, J
机构：
[1] Maimonides Hosp, Brooklyn, NY 11219 USA
[2] Albert Einstein Coll Med, New York, NY USA
[3] Tufts Univ, Sch Med, Medford, MA 02155 USA
[4] Mt Holyoke Coll, S Hadley, MA 01075 USA
来源：
CRITICAL CARE MEDICINE | 2003年 / 31卷 / 01期
关键词：
D O I：
10.1097/00003246-200301000-00049
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：306 / 308
页数：3
相关论文
共 14 条
[1]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[2]   Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis [J].
Angus, DC ;
Linde-Zwirble, WT ;
Clermont, G ;
Ball, DE ;
Basson, BR ;
Ely, EW ;
Laterre, PF ;
Vincent, JL ;
Bernard, G ;
van Hout, B .
CRITICAL CARE MEDICINE, 2003, 31 (01) :1-11
[3]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[4]   THE CLINICAL-EVALUATION OF NEW DRUGS FOR SEPSIS - A PROSPECTIVE-STUDY DESIGN BASED ON SURVIVAL ANALYSIS [J].
KNAUS, WA ;
HARRELL, FE ;
FISHER, CJ ;
WAGNER, DP ;
OPAL, SM ;
SADOFF, JC ;
DRAPER, EA ;
WALAWANDER, CA ;
CONBOY, K ;
GRASELA, TH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (10) :1233-1241
[5]   CUSTOMIZED PROBABILITY-MODELS FOR EARLY SEVERE SEPSIS IN ADULT INTENSIVE-CARE PATIENTS [J].
LEGALL, JR ;
LEMESHOW, S ;
LELEU, G ;
KLAR, J ;
HUILLARD, J ;
RUE, M ;
TERES, D ;
ARTIGAS, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (08) :644-650
[6]  
LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2963
[7]   An economic evaluation of activated protein C treatment for severe sepsis. [J].
Manns, BJ ;
Lee, H ;
Doig, CJ ;
Johnson, D ;
Donaldson, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :993-1000
[8]   Early goal-directed therapy in the treatment of severe sepsis and septic shock. [J].
Rivers, E ;
Nguyen, B ;
Havstad, S ;
Ressler, J ;
Muzzin, A ;
Knoblich, B ;
Peterson, E ;
Tomlanovich, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (19) :1368-1377
[9]   Assessing the use of activated protein c in the treatment of severe sepsis. [J].
Siegel, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :1030-1034
[10]   WHY SEVERITY MODELS SHOULD BE USED WITH CAUTION [J].
TERES, D ;
LEMESHOW, S .
CRITICAL CARE CLINICS, 1994, 10 (01) :93-110
12